OCT O 2 2002 =

Docket No.: 20609/181 (PD-9807)

Examineri Laura Lynn

Stockton

Art Unit: 1626

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Miller et al.

Serial No. : 09/811,838

Filed : March 19, 2001

For : LPA RECEPTOR AGONISTS AND

ANTAGONISTS AND METHODS OF USE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In compliance with 37 C.F.R. 1.56, 1.97, and 1.98, published art included in the International Search Report (copy enclosed) of the corresponding PCT application, is cited for consideration and listed on the enclosed PTO-1449 form.

The International Search Report identifies 12 references. These references are relevant for the reasons given in the search report.

It is our understanding that no fee is required as this Information Disclosure Statement is being filed before a first office action on the merits. See 37 C.F.R. § 1.97(b)(3). However, in the event that a fee is necessary, the Commissioner is authorized to charge PTO Account No. 14-1138 for any such fee.

Respectfully submitted,

Dated: <u>September</u> 27, 2002

Edwin V. Merkel

Registration No. 40,087

NIXON PEABODY LLP

Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (585) 263-1128 Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is before

deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office P.O. BOX 2327 Arlington, VA 22202, on the date below.

Date 9/27/02

CHERIL S. MASCITT